P/E ratio for Blueprint Medicines (BPMC)
P/E ratio as of May 2024 (TTM): -11.8
According to Blueprint Medicines 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.8368. At the end of 2022 the company had a P/E ratio of -4.69.
P/E ratio history for Blueprint Medicines from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.69 | -51.97% |
| 2021 | -9.76 | -148.45% |
| 2020 | 20.1 | -283.48% |
| 2019 | -11.0 | 9.92% |
| 2018 | -9.98 | -48.5% |
| 2017 | -19.4 | 82.45% |
| 2016 | -10.6 | -2.52% |
| 2015 | -10.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pacific Biosciences
PACB | -1.32 | -88.82% | 🇺🇸 USA |
 OPKO Health
OPK | -4.63 | -60.89% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Isoray
ISR | -5.49 | -53.66% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.